For Research Use Only. Not for Human Consumption.
Recorded market$47.36Recorded exact-size market estimate: 47.36 USD for one 50 mg container (0.947163 USD/mg). Arithmetic mean of 10 recorded supplier prices for this same vial or container size and formulation, with no extrapolation from other sizes. Supplier observation dates: Oct 10, 2026 UTC to Oct 11, 2026 UTC. Non-USD prices use ECB exchange rates dated October 9, 2026. Shipping excluded; supplier tax treatment is retained as recorded. This is a dated price comparison, not a former Peptide Serum price or an assurance of potency, purity, dosing or medical equivalence.Public price$47.00Member price$11.3875.9% lessMembers save $35.98 on this item vs. recorded market
Copper tripeptide for dermal and ECM research.
Exact-size price research
Supplier observation dates: Oct 10, 2026 UTC to Oct 11, 2026 UTC. This reference uses recorded prices for the same 50 mg vial or container and formulation. No prices are extrapolated from smaller or larger vials. Peptide Serum member unit prices refresh from the current catalog. Paid PRO membership is required for member pricing.
$0.2276/mg75.9% less
Peptide Serum reference: Member unit price (USD), available with verified paid PRO membership; excludes shipping and applicable taxes. Read from catalog: Oct 23, 2026 04:30 UTC. 1 x 50 mg = 50 mg total.
Source: PeptideSerum-exact-size-market-comparison.xlsx. One selected single-container price per supplier domain, for the same labeled vial size and formulation. Blends match recorded component amounts. The arithmetic mean uses the first ten selected supplier prices in recorded Google discovery order, or the true smaller sample when ten could not be found. No size scaling, mg-to-IU conversion, pack discount or minimum price range is substituted.
The green percentage, when shown, compares the member price for every visitor: (recorded exact-size market average minus Peptide Serum member price) divided by the recorded market average. Unrounded values are used and the percentage is rounded down to one decimal. It is omitted when the member price is equal to or above the reference or the refreshed snapshot cannot be confirmed. Member pricing requires verified paid PRO membership.
These are dated price observations, not live available supplier offers. Shipping is excluded. Supplier tax treatment is retained as recorded and can differ. Memberships, clinical qualifications, ancillary supplies and availability can affect comparability; source notes retain these limitations. Some observations were sold out. Seller domains may be correlated through one manufacturer. This is not a revenue-ranked or complete-market survey.
Non-USD native prices are converted using ECB reference rates dated October 9, 2026. Recorded exchange-rate source. Original prices and currencies are shown below. Currency conversion does not make tax treatment or purchasing conditions identical.
| Source / recorded date | Exact vial / native price | USD per mg | Recorded coverage / conditions |
|---|---|---|---|
| Prism Labs Oct 10, 2026 UTC | One 50 mg container; 34.99 USD | $0.6998/mg | lyophilized powder; in_stock Price observation; no COA authentication is implied by inclusion. |
| Pure Lab Peptides Oct 10, 2026 UTC | One 50 mg container; 59.99 USD | $1.20/mg | lyophilized powder; in_stock Price observation; no COA authentication is implied by inclusion. |
| Pure Bio Labs Oct 10, 2026 UTC | One 50 mg container; 99.99 USD | $2.00/mg | lyophilized powder; in_stock Price observation; no COA authentication is implied by inclusion. |
| Pepta Labs Oct 10, 2026 UTC | One 50 mg container; 36.99 USD | $0.7398/mg | lyophilized powder; in_stock_schema Price observation; no COA authentication is implied by inclusion. |
| PSPeptides Oct 10, 2026 UTC | One 50 mg container; 34.99 USD | $0.6998/mg | lyophilized powder; in_stock_schema Price observation; no COA authentication is implied by inclusion. |
| PeakForm Peptides Oct 10, 2026 UTC | One 50 mg container; 35.00 USD | $0.7000/mg | lyophilized powder; in_stock Price observation; no COA authentication is implied by inclusion. |
| Prime Lab Peptides Oct 11, 2026 UTC | One 50 mg container; 50.00 USD | $1.00/mg | lyophilized powder; InStock Public single-vial GHK-Cu50mg lyophilized powder, quantity1 and explicit USD50. Automatic displayed sale price used; USD67.50 struck price and SAVE15 coupon ignored. Ten-vial pack is separate. Price observation; no COA authentication is implied by inclusion. |
| Peptidic Research Oct 11, 2026 UTC | One 50 mg container; 55.00 USD | $1.10/mg | lyophilized powder; InStock (schema) Public GHK-Cu50mg copper-tripeptide-complex single vial, quantity1, explicit lyophilized powder and USD55 current price. Struck75USD and SAVE20 coupon excluded. Stock from public Offer schema. Price observation; no COA authentication is implied by inclusion. |
| OX Peptides Oct 11, 2026 UTC | One 50 mg container; 35.00 USD | $0.7000/mg | lyophilized powder; 50mg out of stock; Europe-only shipping, unavailable to US Price observation; no COA authentication is implied by inclusion. |
| Nutrigenix Scientific Oct 11, 2026 UTC | One 50 mg container; 45.00 CAD | $0.6326/mg | lyophilized powder; In stock Price observation; no COA authentication is implied by inclusion. |
Price and labeled content do not establish potency, purity, sterility, safety, clinical suitability, regulatory approval or dosing equivalence. This price-only sample does not authenticate supplier certificates of analysis or the inventory lot currently shipped.
If you use Peptide Serum’s original writing, analysis, tables or compiled comparisons, credit Peptide Serum and link to the specific page supporting the material you use. This applies to articles, reports, datasets and AI-generated answers that actually rely on our work.
Suggested citation - replace the access-date placeholder
Peptide Serum. “GHK-Cu – 50 mg | Catalog & Research – Peptide Serum.” https://peptideserum.com/product/ghk-cu-50-mg/ Accessed [your access date].
Source page: https://peptideserum.com/product/ghk-cu-50-mg/
A naturally occurring copper-binding tripeptide studied in dermal biology, extracellular-matrix remodeling, and wound-model research.
Supplied sealed for laboratory handling. Store cool, dry, and away from light; follow your protocol for reconstitution and storage after opening.
For in-vitro laboratory research only. Not for human or veterinary use.
Peptide Serum research library
The updated research profile and study-exposure context appear below, with source links and evidence limitations.
GHK-Cu is a copper complex of the tripeptide glycyl-histidyl-lysine. It is discussed in skin-care and tissue-repair research, but the route and formulation are essential to interpreting a claim. A skin product tested after a procedure is not evidence that injecting GHK-Cu improves skin, hair or whole-body repair.
The copper complex, the uncomplexed GHK peptide and a finished cosmetic formulation are different materials. An ingredient name does not specify concentration, vehicle or delivery to the tissue being studied.
A product should also distinguish the amount of complex from elemental copper or peptide content. A nominal weight without its measurement basis makes both research comparisons and price comparisons ambiguous.
A small randomized post-laser study is directly informative because it compared skin-care regimens with and without GHK-Cu. Thirteen participants completed it. Objective comparisons did not show an advantage for erythema resolution, wrinkles or overall skin quality, while participants using GHK-Cu reported greater satisfaction. Both results belong in the summary.
| Study and design | Finding | What it does not establish |
|---|---|---|
| Topical GHK-Cu after laser resurfacing
Small randomized topical study with 13 completers Reading scope: PubMed abstract |
Objective between-group measures were not significantly different; a patient questionnaire favored the GHK-Cu regimen. | The small post-procedure sample does not establish broader cosmetic effects or any benefit from injections. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
The copper complex and the formulation matter when interpreting GHK-Cu research. In Maquart et al., 1988, fibroblast cultures showed changes in collagen synthesis. That laboratory endpoint provides a reason to investigate tissue biology; it does not by itself demonstrate a visible skin change or a clinical benefit in people.
Maquart et al., 1993 examined wound chambers implanted in rats and measured extracellular-matrix components. GHK-Cu was associated with increased collagen and other matrix contents in that model. A rat wound chamber is different from a clinical wound outcome or the response to a marketed formulation.
These two summaries are based on the primary-study PubMed abstracts checked October 8, 2026. They are selected experimental findings, not a full-text systematic review or evidence that every GHK-Cu product has the same effects.
A statistically significant questionnaire result should not replace the objective null comparisons. It describes participants’ reported experience in this setting, not proof that the ingredient accelerates healing or produces structural rejuvenation.
The selected trial also cannot determine which untested products, concentrations or combinations would behave similarly. Differences in the finished formulation can matter even when the ingredient name is shared.
A useful next study would define the formulation and outcome in advance, include a suitable comparator and enough participants, and report both objective findings and patient experience. A general letter grade would obscure these unresolved questions.
FDA identifies limited human safety information and potential immunogenicity concerns for compounded injectable GHK-Cu. That route-specific entry appears in its withdrawn-nomination table; withdrawal is not approval.
Read any reported exposure together with the concentration, vehicle, skin condition and procedure. A topical ingredient percentage cannot be converted into a systemic dose.
The reviewed evidence does not provide an injectable regimen. A calculator can describe concentration arithmetic but cannot establish a clinical exposure or a safe route.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Ask what the stated mass represents and whether analysis identifies the peptide–copper complex. For a finished topical product, its ingredient list and formulation are more relevant than a COA for a different raw material.
A report on a skin-care ingredient cannot authenticate a separate laboratory vial. The sample, batch and composition must match the item under discussion.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
No. Skin application and injection create different exposure and safety questions. Each claim needs evidence for its actual route and formulation.
It did not show an objective advantage on the reported comparisons. The favorable satisfaction result is a separate finding and should be described that way.
This companion to the GHK-Cu research profile explains how to interpret experimental quantities. It provides no personal-use regimen.
Read any reported exposure together with the concentration, vehicle, skin condition and procedure. A topical ingredient percentage cannot be converted into a systemic dose.
The reviewed evidence does not provide an injectable regimen. A calculator can describe concentration arithmetic but cannot establish a clinical exposure or a safe route.
Find the tested material, formulation, route, study population, comparison group and observation period in the original paper. Exposure in a cell system or animal model does not supply a human starting amount, schedule or route.
Mass describes an amount of material; concentration describes that amount per final solution volume. One milligram equals 1,000 micrograms. Neither a vial label nor arithmetic establishes identity, stability, sterility or an appropriate use.
Read the units reference and the study summaries and their limitations. Use the original methods for the precise experimental conditions; do not transfer a reported amount between different materials or study models.
The main profile links the selected primary sources, distinguishes the study designs and explains what the findings cannot show. A trial registration is a research plan, not a published result.
Reviews
There are no reviews yet.